How can Penumbra balance the cost-effectiveness of its Lightning stroke system with the need for advanced imaging capabilities in its next iteration?

Introduction

Balancing cost-effectiveness with advanced imaging capabilities in Penumbra's Lightning stroke system presents a critical trade-off for the next iteration. This scenario involves weighing the financial considerations against technological advancements in medical imaging. I'll address this challenge by analyzing the product ecosystem, identifying key metrics, designing experiments, and providing a data-driven recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on market trends, I'm thinking advanced imaging might be a key differentiator. Could you share how our competitors are positioning their stroke systems?

Why it matters: Helps understand our competitive landscape and potential market gaps. Expected answer: Competitors are investing heavily in advanced imaging. Impact on approach: Would influence our prioritization of imaging capabilities.

• Considering our business model, I assume the Lightning system is a significant revenue driver. Can you confirm its contribution to our overall revenue?

Why it matters: Determines the financial impact of our decision. Expected answer: It contributes 30-40% of revenue. Impact on approach: Higher contribution would justify more investment in advanced features.

• Looking at user segments, I'm guessing larger hospitals are our primary customers. Is this accurate, and are there emerging segments we're targeting?

Why it matters: Helps tailor our solution to specific user needs. Expected answer: Correct, with growing interest from smaller clinics. Impact on approach: Would influence the balance between advanced features and cost.

• Regarding technical feasibility, I'm curious about our R&D capabilities. How much of our imaging technology is developed in-house versus licensed?

Why it matters: Affects our ability to innovate and control costs. Expected answer: Mostly in-house with some key licensed components. Impact on approach: More in-house capabilities could allow for cost-effective advanced imaging solutions.

• Considering timelines, I'm wondering about regulatory approvals. What's our typical timeline for getting new iterations approved?

Why it matters: Impacts our development and release strategy. Expected answer: 12-18 months for significant changes. Impact on approach: Longer timelines might favor a more ambitious upgrade to justify the wait.